

LightDeck Diagnostics


(Previously MBio Diagnostics, Inc.)



Boulder, CO 80303

<https://LightDeckDx.com/>

(303) 952-2905

SINCE ITS FOUNDING IN**2009****8 SBIR Awards****75 Employees****N/A Socioeconomic Status****6 US Patents from SBIR/STTR****Host-Response Panels at the Point-of-Care**

Lab methods used to assess severe infections are slow and costly. Speed and quality matter in diagnosing and treating sepsis and COVID-19. High quality, fast and simple point-of-care tests are sorely needed to improve outcomes and costs.

The LightDeck platform is built on advanced planar waveguide technology that uses inexpensive, disposable test cartridges and a portable analyzer.

- **Quality:** Highly sensitive tests that deliver lab-quality results
- **Quick:** Actionable results in as little as 5 minutes
- **Quantitative:** More data to inform treatment decisions
- **Multiplex:** Multiple tests per sample plus internal

The prototype host-response system was successfully deployed to the DoD's Uniformed Services University in collaboration with the Henry Jackson Foundation. The demonstration focused on rapid detection of IL-6 during COVID infection.

As part of its ongoing strategy to expand into human clinical diagnostics testing, company name was recently changed from MBio Diagnostics to LightDeck Diagnostics.

IMPACT

The LightDeck platform enables lab-quality testing almost anywhere, from the emergency department to ICU to low-resource settings. Know-how from the host-response programs have been applied to products for COVID-19, cardiac markers to assess chest pain and other IVD products.

Phase II Accomplishments

The COVID-19 Total Antibody Test, funded in part under a BARDA contract of \$629,595, is now available through the FDA Emergency Use Authorization (EUA) process. The Company has raised >\$60M in venture funding and federal contracts, including \$1.8M for two projects with NOAA. Platform technology developed under the DARPA SBIR was the basis of the company's veterinary product commercialization.

Solicitation:*Point-of-care Monitoring of the Host-Pathogen Interaction during Infection***DARPA SBIR Sponsor****SB162-002 Topic Number****Improved Performance Primary Innovation****Greater Reliability Secondary Innovation**